His work has included the development, transfer and launch of three pharmaceutical products which treat disease states such as Type II Diabetes Mellitus, Lymphatic Filiarisis and acute Otitis Media.
He is currently the Global Granulation Leader for Pharmaceutical Development within the GSK R&D organisation. Within this role he has established the first intent principles for various key pharmaceutical operations such as high shear wet granulation, fluid bed drying and roller compaction. More recently he has also been devoting time to the development of various continuous processing unit operations and how they can be deployed within GSK. In addition to this he has been working on how such approaches may become acceptable to potentially conservative external regulatory audiences in the future.
James is a Chartered Chemist and a Fellow of the Royal Society of Chemistry and is based at the GlaxoSmithKline Research facilities in Harlow, UK.